Satellos disclosed six-month interim data from its adult Phase II Trailhead study of SAT-3247 in Duchenne muscular dystrophy. The company reported improvements in muscle fat fraction and effort metrics, with a tolerability profile consistent with earlier findings, as it weighs next regulatory interactions and positions the asset ahead of later pediatric readouts.